Roche has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for its SARS-CoV-2 rapid antigen test. The test allows healthcare professionals to take informed decisions based on quick, reliable results within 15 minutes at point-of-care settings among patients experiencing Covid-19 symptoms.
Avacta has entered into a commercial partnership with Mologic, a rapid diagnostics company, to accelerate its lateral flow Covid-19 antigen test to market. Avacta is one of the first companies to be working on lateral flow tests for Covid-19 using its Affirmer reagents. The antigen tests deliver results within minutes without any laboratory intervention.
Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI and Bio-Techne Corporation, has entered into a marketing and distribution agreement with Atrys Health to expand its global footprint of Covid-19 antibody tests. As per the partnership, Atrys Health will provide Kantaro’s quantitative SARS-CoV-2 IgG antibody test kits, Covid-SeroKlir and Covid-SeroIndex, in Europe and South America, including Brazil, Chile, Colombia, Peru, Portugal, and Spain.
Oxford Immunotec has entered into a memorandum of understanding (MOU) with Green Cross Medical Science (GC MS) and Mesdia, to market the T-SPOT Discovery SARS-CoV-2 kit in South Korea for research use. Under the terms of the agreement, GC MS will market and sell, MESDIA will import, and Oxford Immunotec Korea will offer the overall backing for the kit that measures the T Cell immune response to the SARS-CoV-2 infection.